PRA uses grant funds to expand in Kansas

PRA won a $400,000 grant from the Kansas Bioscience Authority, money the CRO will use to create 80 jobs at its Lenexa, KS, facility.

Quintiles' revenue jumps 4.2% in Q1

Quintiles pulled in $927 million in revenue last quarter, a 4.2% jump over the same period last year the CRO attributes in part to 2012's many acquisitions.

GSK, Allergan marred by CMO setbacks

Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.

Indian clinical trials plunge amid increased scrutiny

India's government is struggling to crack down on loosely regulated clinical trials that have killed hundreds of patients around the country, and while it's unclear if its efforts have made the process safer, they've certainly slowed things down.

Ex-Aptuit researcher jailed over falsified trial results

Steve Eaton, the former Aptuit employee convicted of manipulating data from hundreds of drug safety studies, has been ordered serve three months in jail, the first such sentencing under the U.K.'s tightened research regulations.

Covance bets on Singapore with central lab expansion

Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.

GVK licenses database to U. Dundee's drug development unit

India's GVK Biosciences has licensed its much-cited database of biological targets, GOSTAR, to the University of Dundee's drug discovery unit.

Absorption Systems reaches into India with partnership

U.S. preclinical CRO Absorption Systems has signed a deal with Indian consulting firm Synerzys Lifecare, looking to pitch its testing services to the nation's growing generics market.

Indian CMO Shasun inks Alzheimer's deal with Debiopharm

Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.

Catalent jumps into ADCs with Redwood deal

As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.

inVentiv teams with Japanese CRO to tap growing market

InVentiv Health is betting on a big expansion in Japanese R&D, forming a strategic alliance with local CRO Bell Medical Solutions to offer lab services in the country.

Bristol-Myers picks Quintiles for central lab work

Bristol-Myers Squibb has inked a preferred provider deal with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments.

Indian trial reform on the way, but does it make sense?

India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry.

EU CRO TranScrip launches U.S. operation

TranScrip Partners is coming to America, as the U.K.-based CRO is opening its first stateside office to expand its global footprint.

Quintiles' IPO means $25M for investors

Quintiles is planning to dish out a $25 million payment to its founder and controlling shareholders once it goes public, a termination fee designed to make up for the service fees that won't be paid post-IPO.

InVentiv sells sample management biz to Knipper

Global CRO InVentiv Health is shipping out its sample management business to J. Knipper and focusing instead on its other clinical and commercial offerings.

AmerisourceBergen sells contract packaging biz for $308M

Pharma contracting giant AmerisourceBergen is ditching its commercial packaging business, selling the unit to Frazier Healthcare for $308 million in cash.

Bristol-Myers picks LabCorp for CRO work

CROs competing for big-name deals may face a more crowded market now that on-the-ropes diagnostics companies are getting into the clinical research game, something LabCorp demonstrated this week as it inked a preferred-provider contract with Bristol-Myers Squibb.

CRO turnover rate sky-high, according to survey

CROs have a turnover rate nearly 10 times the national average, according to a new survey, and those numbers could scare off potential clients concerned about a company's internal climate.

Frontage gets FDA chiding over Chinese lab

U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai.